NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.

Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.

More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.

The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.

Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.

As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.

Luminice-203 yields its first topline data, but where are all the patients?

Pfizer moves to take PF-07934040 into its first clinical trial.

The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.